Rpo LLC Buys Shares of 17,293 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Rpo LLC purchased a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 17,293 shares of the biotechnology company’s stock, valued at approximately $77,000. Ironwood Pharmaceuticals makes up approximately 0.1% of Rpo LLC’s holdings, making the stock its 21st biggest holding.

A number of other institutional investors have also recently made changes to their positions in the stock. State Street Corp grew its position in Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after acquiring an additional 677,024 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 4.0% in the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after purchasing an additional 450,949 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Ironwood Pharmaceuticals by 23.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock valued at $7,846,000 after purchasing an additional 364,841 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in Ironwood Pharmaceuticals by 2,625.1% in the fourth quarter. Los Angeles Capital Management LLC now owns 331,700 shares of the biotechnology company’s stock worth $1,469,000 after purchasing an additional 319,528 shares during the last quarter. Finally, Norges Bank bought a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $1,118,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 29th. Craig Hallum cut their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. Finally, JMP Securities lowered their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Ironwood Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $8.60.

Insider Activity

In other news, CMO Michael Shetzline sold 41,269 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. This represents a 6.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 192,381 shares of company stock valued at $338,591. 12.90% of the stock is currently owned by company insiders.

Ironwood Pharmaceuticals Stock Up 2.1 %

IRWD opened at $1.44 on Thursday. The company has a market capitalization of $230.44 million, a PE ratio of -48.00 and a beta of 0.30. Ironwood Pharmaceuticals, Inc. has a 52 week low of $1.32 and a 52 week high of $8.45. The firm has a 50-day simple moving average of $1.90 and a two-hundred day simple moving average of $3.32.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.08). The company had revenue of $90.55 million for the quarter, compared to the consensus estimate of $93.85 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. As a group, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.